» Articles » PMID: 30796690

Selenium Enhances the Apoptotic Efficacy of Docetaxel Through Activation of TRPM2 Channel in DBTRG Glioblastoma Cells

Overview
Journal Neurotox Res
Publisher Springer
Specialty Neurology
Date 2019 Feb 24
PMID 30796690
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The rate of mitosis of cancer cells is significantly higher than normal primary cells with increased metabolic needs, which in turn enhances the generation of reactive oxygen species (ROS) production. Higher ROS production is known to increase cancer cell dependence on ROS scavenging systems to counteract the increased ROS. Therapeutic options which selectively modulate the levels of intracellular ROS in cancers are likely candidates for drug discovery. Docetaxel (DTX) has demonstrated antitumor activity in preclinical and clinical studies. It is thought that DTX induces cell death through excessive ROS production and increased Ca entry. The Ca permeable TRPM2 channel is activated by ROS. Selenium (Se) has been previously used to stimulate apoptosis for the treatment of glioblastoma cells resistant to DTX. However, the potential mechanism(s) of the additive effect of DTX on TRPM2 channels in cancer cells remains unclear. The aim of this study was to evaluate the effect of combination therapy of DTX and Se on activation of TRPM2 in DBTRG glioblastoma cells. DBTRG cells were divided into four treatment groups: control, DTX (10 nM for 10 h), Se (1 μM for 10 h), and DTX+Se. Our study showed that apoptosis (Annexin V and propidium iodide), mitochondrial membrane depolarization (JC1), and ROS production levels were increased in DBTRG cells following treatment with Se and DTX respectively. Cell number and viability, and the levels of apoptosis, JC1, ROS, and [Ca], induced by DTX, were further increased following addition of Se. We also observed an additive increase in the activation of the NAD-dependent DNA repair enzyme poly (ADP-ribose) polymerase-1 (PARP-1) activity, which was accompanied by a decline in its essential substrate NAD. As well, the Se- and DTX-induced increases in intracellular Ca florescence intensity were decreased following treatment with the TRPM2 antagonist N-(p-amylcinnamoyl) anthranilic acid (ACA). Therefore, combination therapy with Se and DTX may represent an effective strategy for the treatment of glioblastoma cells and may be associated with TRPM2-mediated increases in oxidative stress and [Ca].

Citing Articles

TRPM channels in human cancers: regulatory mechanism and therapeutic prospects.

Liu Q, Hu M, Li S, Zhang X, Zhang R, Lyu H Biomark Res. 2024; 12(1):152.

PMID: 39633507 PMC: 11616203. DOI: 10.1186/s40364-024-00699-2.


Targeting Transient Receptor Potential Melastatin-2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer.

Chen Z, Vallega K, Boda V, Quan Z, Wang D, Fan S Adv Sci (Weinh). 2024; 11(35):e2310126.

PMID: 39044361 PMC: 11425210. DOI: 10.1002/advs.202310126.


The Combination of 5-FU and Resveratrol Can Suppress the Growth of Glioblastoma Cells Through Downregulation of TRPM2 and β-Catenin.

Aghababaei F, Nejati M, Karami H, Darvish M, Mirzaei H J Mol Neurosci. 2024; 74(1):7.

PMID: 38193979 DOI: 10.1007/s12031-023-02174-3.


Antioxidant potential of nanomaterials.

Gonzalez-Flores D, Espino J, Pariente J Turk J Biol. 2023; 47(4):218-235.

PMID: 38152621 PMC: 10751091. DOI: 10.55730/1300-0152.2658.


TRPM2: bridging calcium and ROS signaling pathways-implications for human diseases.

Maliougina M, Hiani Y Front Physiol. 2023; 14:1217828.

PMID: 37576339 PMC: 10412822. DOI: 10.3389/fphys.2023.1217828.


References
1.
Gottesman M, Fojo T, Bates S . Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002; 2(1):48-58. DOI: 10.1038/nrc706. View

2.
Naziroglu M, Karaoglu A, Aksoy A . Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats. Toxicology. 2004; 195(2-3):221-30. DOI: 10.1016/j.tox.2003.10.012. View

3.
Saikali S, Avril T, Collet B, Hamlat A, Bansard J, Drenou B . Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy. J Neurooncol. 2006; 81(2):139-48. DOI: 10.1007/s11060-006-9220-3. View

4.
Naziroglu M, Luckhoff A . A calcium influx pathway regulated separately by oxidative stress and ADP-Ribose in TRPM2 channels: single channel events. Neurochem Res. 2008; 33(7):1256-62. DOI: 10.1007/s11064-007-9577-5. View

5.
Naziroglu M, Luckhoff A . Effects of antioxidants on calcium influx through TRPM2 channels in transfected cells activated by hydrogen peroxide. J Neurol Sci. 2008; 270(1-2):152-8. DOI: 10.1016/j.jns.2008.03.003. View